VERU INITIATES PHASE 3 STUDY FOR KIDNEY DISEASE THERAPY ATACICEPT

Veru Therapeutics (NASDAQ:VERU) has initiated a pivotal Phase 3 study of its drug candidate atacicept for the treatment of IgA nephropathy, an autoimmune kidney disorder also known as Berger's disease.

The company will be testing the therapy on IgA nephropathy patients with persistent proteinuria who are at high risk of the disease progressing despite ACEi or ARB therapy.

Veru plans to present results from a Phase 2b study for the drug at the 60th European Renal Association Congress in June.

Veru enters $100M stock purchase agreement with Lincoln Park Capital

Veru stock climbs on sale of ENTADFI capsules business to Blue Water

Veru inks pact to supply FC2 Female Condom to Afaxys Group

Now read: VBI Vaccines gains ahead of upcoming presentation on hep B shot

2023-06-07T18:14:23Z dg43tfdfdgfd